Back to the future: Antibody-based strategies for the treatment of infectious diseases

Simple item page
dc.contributor.authorAkdiş, Cezmi
dc.contributor.buuauthorOral, Haluk Barbaros
dc.contributor.buuauthorÖzakın, C.
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/İmmunoloji Anabilim Dalı/Mikrobiyoloji Bölümü.tr_TR
dc.contributor.scopusid7004498001tr_TR
dc.contributor.scopusid57200678942tr_TR
dc.date.accessioned2021-11-30T10:35:41Z
dc.date.available2021-11-30T10:35:41Z
dc.date.issued2002-07
dc.description.abstractBefore antibiotics, sera from immune animals and humans were used to treat a variety of infectious diseases, often with successful results. After the discovery of antimicrobial agents, serum therapy for bacterial infections was rapidly forsaken. In the last two decades, problems with treatment of newly emerged, re-emerged, or persistent infectious diseases necessitated researchers to develop new and/or improved antibody-based therapeutic approaches. This article reviews some information on the use of antibodies for the treatment of infectious diseases, with special reference to the most seminal discoveries and current advances as well as available treatment approaches in this field.tr_TR
dc.identifier.citationOral, H. B. vd. (2002). "Back to the future: Antibody-based strategies for the treatment of infectious diseases". Molecular Biotechnology, 21(3), 225-236.tr_TR
dc.identifier.endpage239tr_TR
dc.identifier.issn1073-6085
dc.identifier.issue3tr_TR
dc.identifier.pubmed12102547tr_TR
dc.identifier.scopus2-s2.0-0036634582tr_TR
dc.identifier.startpage225tr_TR
dc.identifier.urihttps://doi.org/10.1385/MB:21:3:225
dc.identifier.urihttps://link.springer.com/article/10.1385%2FMB%3A21%3A3%3A225
dc.identifier.urihttp://hdl.handle.net/11452/22886
dc.identifier.volume21tr_TR
dc.identifier.wos000176468500004tr_TR
dc.indexed.pubmedPubmedtr_TR
dc.indexed.scopusScopustr_TR
dc.indexed.wosSCIEtr_TR
dc.language.isoentr_TR
dc.publisherHumana Presstr_TR
dc.relation.collaborationYurt dışıtr_TR
dc.relation.journalMolecular Biotechnologytr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccesstr_TR
dc.subjectImmunoglobulintr_TR
dc.subjectSeptic shocktr_TR
dc.subjectAntibody therapytr_TR
dc.subjectInfectious diseasestr_TR
dc.subjectHuman-immunodeficiency-virustr_TR
dc.subjectTumor-necrosis-factortr_TR
dc.subjectHuman monoclonal-antibodytr_TR
dc.subjectPlacebo-controlled trialtr_TR
dc.subjectIntravenous immunoglobulin therapytr_TR
dc.subjectBone-marrow transplantationtr_TR
dc.subjectGram-negative bacteremiatr_TR
dc.subjectB immune globulintr_TR
dc.subjectLipid-a domaintr_TR
dc.subjectBiochemistry & molecular biologytr_TR
dc.subjectBiotechnology & applied microbiologytr_TR
dc.subjectAnimaliatr_TR
dc.subjectBacteria (microorganisms)tr_TR
dc.subjectCytomegalovirustr_TR
dc.subject.emtreeHepatitis B vaccinetr_TR
dc.subject.emtreeBacterium antibodytr_TR
dc.subject.emtreeMonoclonal antibodytr_TR
dc.subject.emtreeVirus antibodytr_TR
dc.subject.emtreeAntibodytr_TR
dc.subject.emtreeCentoxintr_TR
dc.subject.emtreeChickenpox vaccinetr_TR
dc.subject.emtreeCytomegalovirus vaccinetr_TR
dc.subject.emtreeDiphtheria antibodytr_TR
dc.subject.emtreeHepatitis A vaccinetr_TR
dc.subject.emtreeImmunoglobulintr_TR
dc.subject.emtreeThromboembolismtr_TR
dc.subject.emtreeInterleukin 6 antibodytr_TR
dc.subject.emtreeDrug costtr_TR
dc.subject.emtreeMeasles vaccinetr_TR
dc.subject.emtreeImmunotherapytr_TR
dc.subject.emtreeMumps Vaccinetr_TR
dc.subject.emtreeNeutralizing antibodytr_TR
dc.subject.emtreeBacterial infectiontr_TR
dc.subject.emtreeRabies vaccinetr_TR
dc.subject.emtreeAseptic meningitistr_TR
dc.subject.emtreeRubella vaccinetr_TR
dc.subject.emtreeAntimicrobial activitytr_TR
dc.subject.emtreeTetanus antibodytr_TR
dc.subject.emtreeAntigen bindingtr_TR
dc.subject.emtreeTumor necrosis factor antibody animaltr_TR
dc.subject.emtreeBacterial infectiontr_TR
dc.subject.emtreeRevie antibody productiontr_TR
dc.subject.emtreeHumantr_TR
dc.subject.emtreeDrug researchtr_TR
dc.subject.emtreeImmunotherapytr_TR
dc.subject.emtreeInfectiontr_TR
dc.subject.emtreeDrug usetr_TR
dc.subject.emtreeInfectiontr_TR
dc.subject.emtreeKidney failuretr_TR
dc.subject.emtreeNonhumantr_TR
dc.subject.meshAnimalstr_TR
dc.subject.meshAntibodies, bacterialtr_TR
dc.subject.meshAntibodies, monoclonaltr_TR
dc.subject.meshVirus diseasestr_TR
dc.subject.meshAntibodies, viraltr_TR
dc.subject.meshInfectiontr_TR
dc.subject.meshBacterial infectionstr_TR
dc.subject.meshImmunotherapytr_TR
dc.subject.meshHumanstr_TR
dc.subject.meshAnimaltr_TR
dc.subject.meshBacterial infectionstr_TR
dc.subject.meshHumantr_TR
dc.subject.meshImmunotherapytr_TR
dc.subject.meshVirus diseasestr_TR
dc.subject.scopusRespiratory Distress Syndrome, Adult; Allied Health Personnel; Disaster Disastertr_TR
dc.subject.wosBiochemistry & molecular biologytr_TR
dc.subject.wosBiotechnology & applied microbiologytr_TR
dc.titleBack to the future: Antibody-based strategies for the treatment of infectious diseasestr_TR
dc.typeReview
dc.wos.quartileQ3 (Biotechnology & applied microbiology)tr_TR
dc.wos.quartileQ4 (Biochemistry & molecular biology)tr_TR

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science